Quintiles Speeds Patient Recruitment with Local Marketing Automation Technology

Quintiles Speeds Patient Recruitment with Local Marketing Automation Technology
RALEIGH, N.C.--(BUSINESS WIRE)--Quintiles today launched innovative, web-based technology to enable world-class marketing for clinical trial enrolment at an individual site-level. Named Quintiles Trial Enrolment Accelerator (QTEA), this new solution will speed patient recruitment by helping customers better manage the quality, consistency and effectiveness of messaging and media outreach.

"Direct outreach has become a vital component of on-time patient recruitment with consistent evidence of breakthrough effectiveness. However, some biopharma companies are still reluctant to invest up-front in fully integrated, high quality communication plans for their studies"
."On-time patient recruitment is the biggest challenge in clinical research today," said Chris Cabell, Senior Vice President, Access to Patients, Quintiles. "Every day lost in recruitment potentially delays access to new and better medicines and is hugely expensive - for each day a drug is delayed it costs the biopharmaceutical industry up to $8 million in revenue[1].

"Direct outreach has become a vital component of on-time patient recruitment with consistent evidence of breakthrough effectiveness. However, some biopharma companies are still reluctant to invest up-front in fully integrated, high quality communication plans for their studies," Cabell said. "This means that responsibility for creating and placing materials is typically left to individual sites, giving rise to inconsistency, poor returns on investment and little to no visibility of program effectiveness."

QTEA is exclusively available through Quintiles and allows biopharma companies to benefit from the effectiveness of a centralized patient outreach campaign without the usual high costs. It facilitates creation of consistent, branded recruitment materials for all sites, based on a full range of standard templates. It then helps them to capitalize on existing local media intelligence and increased negotiating power to reduce media costs by up to 50%. It also provides access to Quintiles proprietary opt-in patient database and referral network to drive highly efficient one-to-one marketing.

Quintiles Trial Enrolment Accelerator helps customers to navigate the risks associated with patient recruitment," Cabell continued, "to achieve better utilization of dollars, greater return on investment, faster patient recruitment and real-time reporting for visibility into program success."

To help customers get the most from QTEA Quintiles provides consultation on building a study-specific campaign, with communication elements designed for the protocol. QTEA integrates with QRecruit, a web-based patient screening tool, and is part of Quintiles' industry leading holistic patient recruitment solution to better find, enrol and retain patients throughout a study.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

[1] October, 2005. Hess, Jon. Web-based Patient Recruitment. Cutting Edge Information.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6182774&lang=en

or http://www.quintiles.com/information-library/videos/quintiles-trial-enrollment-accelerator/

Contacts
Quintiles
Charlotte Taylor, Media Relations
[email protected]
+441344 708 386
or
Greg Connors, Investor Relations
[email protected]
+1 919 998 2000

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.